Vicore Pharma Holding AB
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases. The group operates through Vicore Pharma AB and Vicore Pharma US Inc., with its main office in Stockholm and a listed presence in Stockholm and the U.S.
Liiketoiminta
Osuus liikevaihdostaInvestigational therapies advanced through preclinical and clinical development.
Early-stage programs and target discovery around ATRAG-based biology.
Scientific, development, and business support activities within the group.
Asiakkaat
Vicore is not a traditional commercial drug seller; its direct counterparties are primarily hospitals, clinical research sites, CROs, and laboratory partners that support the development program. Ultimate beneficiaries are patients and physicians in severe respiratory and fibrotic diseases, while future commercial buyers would be specialty prescribers and healthcare systems if a candidate is approved.
Hospitals, clinics, and investigators participating in Vicore-sponsored trials and patient recruitment.
External partners providing trial management, scientific services, and development execution.
Academic and industry partners contributing to discovery and translational science.
Pulmonologists and specialty centers that would use an approved therapy in severe lung disease.
Strategia
Vicore's strategy centers on advancing buloxibutid through clinical development while building a broader pipeline around ATRAG biology. The company also expands its research foundation and external development capabilities to support later-stage value creation and potential partnering options.
Clinical progress is the main value driver for a development-stage biotech company.
A broader pipeline reduces dependence on one asset and creates long-term platform value.
Deeper biology and discovery capabilities support better target selection and differentiation.
Maantiede
Vicore is headquartered in Stockholm, Sweden, and the group includes a U.S. subsidiary for local development and business support. Its operating footprint is tied to clinical and research activity rather than broad commercial manufacturing, so geography mainly reflects where trials, scientific work, and corporate functions are organized.
Riskit
Vicore's business is exposed to the high failure rate of pharmaceutical R&D, where most projects do not reach approval and clinical programs can be delayed by efficacy, safety, enrollment, or manufacturing issues. As a development-stage biotech, it also depends on continued funding and execution across a small number of programs, which makes setbacks in any one asset material.
- Clinical trial failure or delayVaikutus: KriittinenTodennäköisyys: Kohtalainen
The lead asset must show efficacy and tolerability in trials before value can be realized.
Kohdistuu: Buloxibutid and other clinical programs
- Patient recruitment and site execution riskVaikutus: KorkeaTodennäköisyys: Korkea
Enrollment and trial conduct can slow development timelines and increase costs.
Kohdistuu: Phase 2b and future respiratory studies
- Financing and capital intensityVaikutus: KorkeaTodennäköisyys: Korkea
R&D-heavy biotech models consume cash before commercialization and may need repeated funding.
Kohdistuu: Group funding needs
- Pipeline concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A limited number of programs makes the company vulnerable to setbacks in one asset.
Kohdistuu: Buloxibutid and ATRAG discovery
Kirjanpito
Harkinnanvaraiset erätThe report notes reclassification of accrued R&D balances between prepaid expenses and accrued income for comparability.
Vaikutus: Can change expense timing and balance sheet presentation without altering cash flow.
Parent and subsidiaries invoice each other for business support and R&D services.
Vaikutus: Affects consolidation eliminations and local entity results.
Unconditional contributions from the parent to the subsidiary provide funding support.
Vaikutus: Impacts equity financing presentation rather than operating revenue.
Development-stage companies typically expense most research and development costs as incurred.
Vaikutus: Shapes reported losses and makes period-to-period comparability dependent on trial timing.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Immunocore Holdings plc
IMCR · Biological Products, (No Diagnostic Substances)
Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to…
aTyr Pharma, Inc
ATYR · Biological Products, (No Diagnostic Substances)
aTyr Pharma is a U.S.-based biotechnology company focused on discovering and developing protein-based therapeutics derived from tRNA synthetase biology.
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Fulcrum Therapeutics, Inc.
FULC · Pharmaceutical Preparations
Päivitetty: 28.9.2026